When President Barack Obama called for a national moon shot to end cancer, the MD Anderson community and our patients cheered. For nearly 75 years, cancer has been our priority, and we are heartened to see it elevated to a true national priority.
Annual Report 2015 : Research
Bottom line: Converting discoveries into new treatments at a faster rate
When a clinical trial for a new breast cancer drug launched recently, researchers estimated it would take at least two years to enroll the 20 patients needed to make the trial a success. However, within four months, half the patients had already enrolled ¡ª and the drug worked for all 10.
Associate professor of Breast Medical Oncology Jennifer Litton, M.D. Photo: Nick de la Torre
¡°That¡¯s the power of the ,¡± says , associate professor of Breast Medical Oncology and the trial¡¯s principal investigator.
Accelerating the conversion of scientific knowledge into new treatments for patients is a priority of the program.
¡°What moon shots has done for my patients is cut the time it takes to go from a clinical trial idea to the time a person gets a new drug down from three years to about one. That¡¯s huge,¡± says Litton, an experienced leader of clinical trials.
The drug, called talozoparib, is currently being tested in late-stage breast cancer patients who have BRCA1 and 2 gene mutations and whose disease has spread.
Those who test positive for BRCA mutations have a significantly higher risk of developing breast and ovarian cancers, as well as passing on the mutation to future generations.
Owned by Medivation Inc., talozoparib is what is known as a PARP inhibitor. PARP ¡ª short for Poly (ADP-ribose) polymerase ¡ª is an enzyme that helps repair damaged DNA. In cancer treatment, blocking PARP may prevent such repairs, causing the cells to die.
Litton¡¯s trial uses a new targeted therapy for two months before proceeding to standard of care chemotherapy followed by surgery. The trial and accompanying moon shot studies will provide a detailed view of talozoparib in first-line use.
¡°In this and other studies, we¡¯ve found that when companies know we have the moon shot behind us, we¡¯ve been given access to drugs they won¡¯t give to anyone else for investigator-initiated trials because we can promise them the trial will happen,¡± Litton says.
Not only does the moon shot provide funding for the study, it supplies a deep roster of scientists drawing on expertise from across the institution to provide the pharmaceutical corporation an unprecedented opportunity to learn about its drug.
¡°It¡¯s low risk for them. And on top of that, they¡¯re getting correlative study information they can¡¯t get from other places now.¡±
The previously untreated patients enrolled in Litton¡¯s trial have biopsies done before and after treatment. Moon shot co-leader Gordon Mills, M.D., Ph.D., chair of Systems Biology, will oversee genetic and molecular analysis of the tumors both before and after. Provost Helen Piwnica- Worms, M.D., Ph.D., will cultivate grafts of the human tumors in mouse models to further understand the mechanisms of the disease and drug.
More Stories From Annual Report
In 2015, surgical history was made
Collaboration and a unique opportunity led to the world¡¯s first skull and scalp transplant
Curing leukemia without debilitating side effects
Jamie Whittington has an aggressive form of chronic lymphocytic leukemia, but you¡¯d never know it.
An immunotherapy drug to bolster a T cell surge
MD Anderson Melanoma Moon Shot researchers are combining two immunotherapies for the first time to double-team melanoma that has spread to other organs and resisted all forms of treatment.
Bold advances require the latest technology
To meet a growing demand for clinical, diagnostic and support services, ground was broken in 2013 for The Pavilion, an eight-story, 184,800-square-foot facility connected to the Main Building.
In the face of cancer
It¡¯s a phrase that describes our patients, who, faced with a disease that is unpredictable and unforgiving, remain strong and determined.
It describes our doctors, researchers, educators and staff, who are relentless in their drive to stop a plague that robs us all of friends, family and loved ones.
He took on the mystery of metastasis. Now he¡¯s taking on brain cancer.
Few scientists have devoted as much of their career to understanding how cancer spreads as Isaiah Fidler, D.V.M., Ph.D.
Graduating to big things before returning to MD Anderson
When Joya Chandra, Ph.D., joined the faculty of MD Anderson¡¯s pediatrics department in 2002, she felt an immediate kinship with the researchers, clinicians and, especially, with the students.
Where rivers of research and clinical data converge into one pool
A simple yet unprecedented goal drives the big data efforts of MD Anderson¡¯s Moon Shots Program: to have every patient contribute to and benefit from the cancer
center¡¯s research.
Outsmarting cancer with genetic testing
Teresa Hall¡¯s visit to a gastroenterologist three years ago wasn¡¯t the first time she¡¯d sought help for troubling symptoms.
Are you at high risk for pancreatic cancer?
A new clinic to identify and monitor those at high risk for developing pancreatic cancer continues to expand after opening last year.
We¡¯re creating partnerships to detect a deadly cancer earlier
Building on MD Anderson research, a new company named Codiak Biosciences has formed to create therapeutic and diagnostic products using exosomes ¡ª small parts of cells that break away and float around the body.
Breast cancer screening guidelines aren¡¯t a one-size-fits-all solution
It¡¯s clear that breast cancer screenings save lives. But exactly when women at average risk of developing breast cancer should begin screening is much less clear.
